Herbert L. DuPont

Prof. Herbert L. DuPont

The University of Texas Health Science Center at Houston, Houston, Texas, USA
orcid
Current Appointments: Professor of Infectious Diseases and E...

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2011 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CBC. Bavishi
C. Bavishi
HDHerbert L. DuPont
Herbert L. DuPont

21 February 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
ZJZ. D. Jiang
Z. D. Jiang
NAN. J. Ajami
N. J. Ajami
JPJ. F. Petrosino
J. F. Petrosino
GJG. Jun
G. Jun
CHC. L. Hanis
C. L. Hanis
HDHerbert L. DuPont
Herbert L. DuPont
Summary: Background: Faecal microbiota transplantation (FMT) has become routine in managing recurrent C. difficile infection (CDI) refractory to antibiotics.Aim: To compare clinical response and improvements in colonic microbiota diversity in subjects with recurrent CDI using different donor product.Methods: Seventy‐two subjects with ≥3 bouts of CDI were randomised in a double‐blind study to receive fresh, frozen or lyophilised FMT product via colonoscopy from 50 g of stool per treatment from eight healthy donors. Recipients provided stools pre‐ and 7, 14 and 30 days post‐FMT for C. difficile toxin and, in a subset, microbiome composition by 16S rRNA gene profiling.Results: Overall resolution of CDI was 87% during 2 months of follow‐up after FMT. Stool samples before FMT had significantly decreased bacterial diversity with a high proportion of Proteobacteria compared to donors. Cure rates were highest for the group receiving fresh product seen in 25/25 (100%), lowest for the lyophilised product 16/23 (78%; P = 0.022 vs. fresh and 0.255 vs. frozen) and intermediate for frozen product 20/24 (P = 0.233 vs. fresh). Microbial diversity was reconstituted by day 7 in the subjects receiving fresh or frozen product. Improvement in diversity was seen by day 7 in those randomised to lyophilised material with reconstitution by 30 days.Conclusions: Comparative efficacy in faecal microbiota transplantation was observed in subjects receiving fresh or frozen faecal product from the same donors. The lyophilised product had a slightly lowered efficacy compared with fresh product, but it resembled other treatments in microbial restoration 1 month after faecal microbiota transplantation.

14 June 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
THTaylor M. Halsey
Taylor M. Halsey
ATAnusha S. Thomas
Anusha S. Thomas
THTomo Hayase
Tomo Hayase
WMWeijie Ma
Weijie Ma
HAHamzah Abu-Sbeih
Hamzah Abu-Sbeih
Yinghong WangYinghong Wang
Yinghong Wang
Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC). Given the association between gut bacteria with response to ICI therapy and subsequent IMC, fecal microbiota transplantation (FMT) represents a feasible way to manipulate microbial composition in patients, with a potential benefit for IMC. Here, we present a large case series of 12 patients with refractory IMC who underwent FMT from healthy donors as salvage therapy. All 12 patients had grade 3 or 4 ICI-related diarrhea or colitis that failed to respond to standard first-line (corticosteroids) and second-line immunosuppression (infliximab or vedolizumab). Ten patients (83%) achieved symptom improvement after FMT, and three patients (25%) required repeat FMT, two of whom had no subsequent response. At the end of the study, 92% achieved IMC clinical remission. 16SrRNA sequencing of patient stool samples revealed that compositional differences between FMT donors and patients with IMC before FMT were associated with a complete response after FMT. Comparison of pre- and post-FMT stool samples in patients with complete responses showed significant increases in alpha diversity and increases in the abundances ofCollinsellaandBifidobacterium, which were depleted in FMT responders before FMT. Histologically evaluable complete response patients also had decreases in select immune cells , including CD8+T cells, in the colon after FMT when compared with non-complete response patients (n= 4). This study validates FMT as an effective treatment strategy for IMC and gives insights into the microbial signatures that may play a critical role in FMT response.

2 March 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
HDHerbert L. DuPont
Herbert L. DuPont
JSJessika Suescun
Jessika Suescun
ZJZhi-Dong Jiang
Zhi-Dong Jiang
EBEric L. Brown
Eric L. Brown
HEHeather T. Essigmann
Heather T. Essigmann
MSMya C. Schiess
Mya C. Schiess
Background and purpose: The intestinal microbiome plays a primary role in the pathogenesis of neurodegenerative disorders and may provide an opportunity for disease modification. We performed a pilot clinical study looking at the safety of fecal microbiota transplantation (FMT), its effect on the microbiome, and improvement of symptoms in Parkinson's disease.Methods: This was a randomized, double-blind placebo-controlled pilot study, wherein orally administered lyophilized FMT product or matching placebo was given to 12 subjects with mild to moderate Parkinson's disease with constipation twice weekly for 12 weeks. Subjects were followed for safety and clinical improvement for 9 additional months (total study duration 12 months).Results: Fecal microbiota transplantation caused non-severe transient upper gastrointestinal symptoms. One subject receiving FMT was diagnosed with unrelated metastatic cancer and was removed from the trial. Beta diversity (taxa) of the microbiome, was similar comparing placebo and FMT groups at baseline, however, for subjects randomized to FMT, it increased significantly at 6 weeks (p = 0.008) and 13 weeks (p = 0.0008). After treatment with FMT, proportions of selective families within the phylum Firmicutes increased significantly, while proportion of microbiota belonging to Proteobacteria were significantly reduced. Objective motor findings showed only temporary improvement while subjective symptom improvements were reported compared to baseline in the group receiving FMT. Constipation, gut transient times (NS), and gut motility index (p = 0.0374) were improved in the FMT group.Conclusions: Subjects with Parkinson's disease tolerated multi-dose-FMT, and experienced increased diversity of the intestinal microbiome that was associated with reduction in constipation and improved gut transit and intestinal motility. Fecal microbiota transplantation administration improved subjective motor and non-motor symptoms.Clinical trial registration: ClinicalTrial.gov, identifier: NCT03671785.

17 April 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
HDHerbert L. DuPont
Herbert L. DuPont
In the United States, there are approximately 179 million cases of acute diarrhea per year. This update on the diagnosis and management of acute diarrhea in immunocompetent adults gives particular attention to the roles of noroviruses and Clostridium difficile.

1 November 2018 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
EVEvangelia Valilis
Evangelia Valilis
ARAlison Ramsey
Alison Ramsey
SSSaad Sidiq
Saad Sidiq
HDHerbert L. DuPont
Herbert L. DuPont
Non-O157 strains of Shiga toxin-producing Escherichia coli (STEC) are more common causes of acute diarrhea than the better-known O157 strains and have the potential for large outbreaks. This systematic review of the literature identified 129 serogroups as well as 262 different O and H antigen combinations of STEC in cases of epidemic and sporadic disease worldwide. Excluding the results from a single large outbreak of STEC O104:H4 in Germany and France in 2011, the reported frequency of dysenteric illness in patients was 26% (119 of 464) for epidemic disease and 25% (646 of 2588) for sporadic cases. Hemolytic uremic syndrome was identified in 14% of epidemic disease cases and 9% of sporadic illness cases. With the increasing use of PCR-based diagnostics, STEC strain identification may not be possible. Rapid diagnostics are needed for STEC infections to aid the clinician while allowing epidemiologists the opportunity to identify outbreaks and to trace the source of infection.